In patients with systemic lupus erythematosus (SLE), immature B cells that recognize self antigens fail to undergo apoptosis or suppression before maturation; one consequence is that untreated ...

B cells have important pathogenic roles in systemic lupus erythematosus (SLE): they produce autoantibodies, secrete inflammatory cytokines and might promote expansion of autoreactive T cells via ...

It is currently being studied for both cutaneous and systemic lupus erythematosus (SLE). Obinutuzumab (Gazyva®) is a treatment that works by blocking the activation of B cells, which contribute to ...

Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient.

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Primary outcome measures were evaluation of frequency and rate of adverse events at 12 and 24 weeks, as well as baseline change in B cell and B-cell ... measures: SS, SLE flare Index (SFI ...

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...